Ilham Legssyer | Researchain

Archive Network Publication Hotspot Collaboration

Network

Latest external collaboration on country level. Dive into details by clicking on the dots.

Explore More

Hotspot

Dive into the research topics where Ilham Legssyer is active.

Explore More

Publication

Featured researches published by Ilham Legssyer.

Clinical and Experimental Dermatology | 2006

High serum galectin-3 in advanced melanoma: preliminary results

Pierre Vereecken; Karim Zouaoui Boudjeltia; Charles Debray; Ahmad Awada; Ilham Legssyer; François Sales; Michel Petein; Michel Vanhaeverbeek; Ghanem Elias Ghanem; Michel Heenen

Background. Galectin‐3 (Gal‐3) is a member of the family of β‐galactoside‐binding mammalian lectins, and has been implicated in tumour invasion and metastatic process in vitro and in vivo.

Biochemical and Biophysical Research Communications | 2004

Oxidation of low density lipoproteins by myeloperoxidase at the surface of endothelial cells: an additional mechanism to subendothelium oxidation

K. Zouaoui Boudjeltia; N. Moguilevsky; Ilham Legssyer; Sajida Babar; M. Guillaume; Paul Delrée; M. Vanhaeverbeek; D. Brohee; J. Ducobu; ClaudeRemacleC. Remacle

Biochemical and Biophysical Research Communications | 2005

Thiol-containing molecules interact with the myeloperoxidase/H2O2/chloride system to inhibit LDL oxidation.

Pierre Van Antwerpen; Karim Zouaoui Boudjeltia; Sajida Babar; Ilham Legssyer; Patrick Moreau; Nicole Moguilevsky; Michel Vanhaeverbeek; Jean Ducobu; Jean Neve

Biochemical and Biophysical Research Communications | 2004

Monoclonal antibodies against LDL progressively oxidized by myeloperoxidase react with ApoB-100 protein moiety and human atherosclerotic lesions.

Nicole Moguilevsky; K. Zouaoui Boudjeltia; S. Babar; Paul Delrée; Ilham Legssyer; Y. Carpentier; M. Vanhaeverbeek; J. Ducobu

Bioorganic & Medicinal Chemistry | 2008

Conception of myeloperoxidase inhibitors derived from flufenamic acid by computational docking and structure modification

Pierre Van Antwerpen; Martine Prévost; Karim Zouaoui-Boudjeltia; Sajida Babar; Ilham Legssyer; Patrick Moreau; Nicole Moguilevsky; Michel Vanhaeverbeek; Jean Ducobu; Jean Neve; François Dufrasne

European Journal of Pharmacology | 2006

Captopril inhibits the oxidative modification of apolipoprotein B-100 caused by myeloperoxydase in a comparative in vitro assay of angiotensin converting enzyme inhibitors

Pierre Van Antwerpen; Ilham Legssyer; Karim Zouaoui Boudjeltia; Sajida Babar; Patrick Moreau; Nicole Moguilevsky; Michel Vanhaeverbeek; Jean Ducobu; Jean Neve

Journal of Cardiovascular Pharmacology | 2007

Probucol does not inhibit myeloperoxidase-dependent low-density lipoprotein oxidation as a potent protective effect in atherosclerosis

Pierre Van Antwerpen; Jean Neve; Patrick Moreau; Karim Zouaoui Boudjeltia; Michel Vanhaeverbeek; Martine Prévost; Sajida Babar; Ilham Legssyer; Nicole Moguilevsky; Jean Ducobu

Archive | 2007

Inhibition de l'oxydation des LDLs par la myeloperoxydase humaine: nouvelle approche pharmacologique dans l'athérosclérose

Pierre Van Antwerpen; François Dufrasne; Martine Prévost; Karim Zouaoui Boudjeltia; S. Babar; Ilham Legssyer; Patrick Moreau; Nicole Moguilevsky; Michel Vanhaeverbeek; Jean Ducobu; Jean Neve

Archive | 2007

Inhibition by several therapeutical agents of myeloperoxidase - dependent LDL oxidation

Pierre Van Antwerpen; Karim Zouaoui Boudjeltia; François Dufrasne; Martine Prévost; Ilham Legssyer; Sajida Babar; Patrick Moreau; Paul G. Furtmüller; Christian Obinger; Michel Vanhaeverbeek; Jean Ducobu; Jean Neve

Atherosclerosis Supplements | 2007